Active substance
Rupatadine
- SFDA 2
- Health Canada 5
- NHS prices 2
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| PAFINUR 10 mg Tablet | 10 mg | Tablet · Oral use | 20 Blister | SAR 23.80 | NCE · Prescription | Nocour Health S.A | Valid |
| Pafinur | 1 mg/ml | Oral solution · Oral use | 1 Bottle | SAR 31.25 | NCE · Prescription | NOCOUR HEALTH S.A | Valid |
Indications — CHI Daman Drug Formulary
ALLERGIC CONJUCTIVITIS (AC); ALLERGIC RHINITIS; HUMAN IMMUNODEFICIENCY VIRUS; TUBERCULOSIS-SUPPORTIVE CARE
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| APO-RUPATADINE | 02553155 | 10 MG | TABLET · ORAL | APOTEX INC |
| PMS-RUPATADINE | 02552604 | 10 MG | TABLET · ORAL | PHARMASCIENCE INC |
| RIVA-RUPATADINE | 02560119 | 10 MG | TABLET · ORAL | LABORATOIRE RIVA INC. |
| RUPALL | 02456451 | 10 MG | TABLET · ORAL | MEDEXUS PHARMACEUTICALS INC. |
| RUPALL | 02456478 | 1 MG / ML | SOLUTION · ORAL | MEDEXUS PHARMACEUTICALS INC. |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| NHS Drug Tariff | Rupatadine 10mg tablets | £75.82 | 30 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Rupatadine 1mg/ml oral solution | £9.95 | 120 ml | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.